永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06978 永泰生物-B

交易中 09-25 10:54:45

0.400

+0.000

0.00%

最高0.400	最低0.400	成交量0.00
今开0.400	昨收0.400	日振幅0.00%
总市值2.47亿	流通市值2.47亿	总股本6.18亿
成交额0.00	换手率0.00%	流通股本6.18亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06978","market":"HK","secType":"STK","nameCN":"永泰生物-B","latestPrice":0.4,"timestamp":1790298005002,"preClose":0.4,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":618000000,"shares":618000000,"eps":-0.4903514001098126,"marketStatus":"交易中","change":0,"latestTime":"09-25 10:54:45","open":0.4,"high":0.4,"low":0.4,"amount":0,"amplitude":0,"askPrice":0.4,"askSize":8000,"bidPrice":0.375,"bidSize":20000,"shortable":0,"etf":0,"ttmEps":-0.33354986489136407,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1790308800000},"marketStatusCode":2,"adr":0,"listingDate":1594310400000,"exchange":"SEHK","adjPreClose":0.4,"openAndCloseTimeList":[[1790299800000,1790308800000],[1790312400000,1790323200000]],"volumeRatio":0,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06978","defaultTab":"news","newsList":[{"id":"2669936644","title":"【千亿药企龙头深度拆解】六大创新药企财务复盘与估值体系剖析","url":"https://stock-news.laohu8.com/highlight/detail?id=2669936644","media":"港股解码","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669936644?lang=zh_cn&edition=full","pubTime":"2026-09-24 16:33","pubTimestamp":1790238780,"startTime":"0","endTime":"0","summary":"整体来看，公司高估值更多来源于赛道成长性与创新预期，是创新药企早期发展阶段较为常见的估值特征。石药集团整体估值偏低，与其稳健均衡的业务结构高度相关。恒瑞医药年内股价有所下挫、估值阶段性承压。结语从赛道业态、竞争格局、管线技术的定性拆解，到2026年上半年财务基本面、估值定价逻辑的定量验证，完成了六家港股千亿创新药企的复盘。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzI2MDAzMTQ4OA==&mid=2650514309&idx=1&sn=d8d9de113e4dd11426fdf82a1e5b119f&chksm=f3f9c4fb4aa82273e1ff070f04fc5a1f473c8c2ec565d519f3aafbb0b149443b89ecad645b61&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["BK1161","06978","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669454461","title":"先直线拉升，后暴跌！创新药龙头，午后公布利好","url":"https://stock-news.laohu8.com/highlight/detail?id=2669454461","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669454461?lang=zh_cn&edition=full","pubTime":"2026-09-24 13:58","pubTimestamp":1790229480,"startTime":"0","endTime":"0","summary":"9月24日午后，诺诚健华午后走出“过山车”行情，开盘后先直线拉升，从-6.41%拉升至涨近1.7%，股价创出历史新高，达到35元/股。不过，冲高之后，股价又快速回落，截至最新，跌幅超10%。今日 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260924/c680252789.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260924/c680252789.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["LNGR","159992","IBBQ","MEDX","BK1574","06978","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669566734","title":"港股异动 | 创新药概念股全线回落 美联储加息预期冲击创新药行业 机构指BD政策风险边际缓和","url":"https://stock-news.laohu8.com/highlight/detail?id=2669566734","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669566734?lang=zh_cn&edition=full","pubTime":"2026-09-24 11:56","pubTimestamp":1790222187,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","06978","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669430903","title":"【券商聚焦】国金证券：中国双抗/ADC/小核酸具全球竞争力，有望催化创新药新一轮出海与估值重估","url":"https://stock-news.laohu8.com/highlight/detail?id=2669430903","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669430903?lang=zh_cn&edition=full","pubTime":"2026-09-24 09:05","pubTimestamp":1790211910,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国金证券研究指，2026 WCLC首尔召开，中国创新药密集登场：康方依沃西一线NSCLC头对头优效帕博利珠，PD-1/VEGF双抗领跑IO2.0；翰森/宜联B7-H3ADC进全体会场，ADC向前线+围手术期迁移；KRAS G12D、HER2、EGFR耐药等精准治疗破局。中国双抗/ADC/小核酸具全球竞争力，数据国际领先，有望催化创新药新一轮出海与估值重估。风险提示：新药研发失败风险；研发进度低于预期风险；药品降价风险。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250110/YzMzOTE1NTA2MzA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/YzMzOTE1NTA2MzA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992369","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159992","01877","06978","LU0314109678.HKD","600109","LU0348784397.USD","LU0039217434.USD","LU0320764599.SGD","LU0315179316.USD","LNGR","LU0348766576.USD","LU1226288253.USD","09995","KURE","LU0516423091.SGD","06160","LU1770034418.SGD","IBBQ","KCE","IE00B5MMRT66.SGD","LU0708995583.HKD","LU1152091168.USD","02142","SG9999002562.SGD","LU1251922891.USD","01093","LU2039709279.SGD","01177","06185","LU0348735423.USD","LU1152091754.HKD","LU2476274720.SGD","LU2097828805.USD","09926","02269","LU0128526141.USD","HK0000165453.HKD","LU0359202008.SGD","LU3063872942.SGD","09688","LU0828237510.HKD","LU1719994722.HKD","LU0029874061.USD","LU1226287792.SGD","02616","MEDX","BK1515","01801","LU0417516902.SGD","LU1993786604.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669103169","title":"【券商聚焦】兴业证券维持先声药业（02096）增持评级 指创新药高增推动盈利提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2669103169","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669103169?lang=zh_cn&edition=full","pubTime":"2026-09-23 15:12","pubTimestamp":1790147547,"startTime":"0","endTime":"0","summary":"2026年上半年，公司实现收入45.80亿元人民币，归母净利润8.29亿元人民币，经调整归母净利润9.64亿元人民币；创新药业务收入38.87亿元人民币，占总收入84.9%。神经科学收入20.09亿元人民币，占比43.9%；自身免疫收入12.10亿元人民币，占比26.4%；肿瘤领域收入9.25亿元人民币。该交易达成后，先声药业累计完成6项对外授权，潜在总交易金额超过61亿美元。","market":"other","thumbnail":"https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992285","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBBQ","159992","02096","601377","06978","KCE","LNGR","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669103660","title":"本轮创新药行情的一个新变化：“湿实验”正在成为AI制药时代核心资产","url":"https://stock-news.laohu8.com/highlight/detail?id=2669103660","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669103660?lang=zh_cn&edition=full","pubTime":"2026-09-23 15:07","pubTimestamp":1790147236,"startTime":"0","endTime":"0","summary":"两条新闻隔了三个月，指向同一个判断：这一轮AI制药，模型是易耗品，数据是燃料，而生产数据的地方——湿实验室，正在从成本中心变成资产负债表上最硬核的一项资产。但里程碑的每一次触发，都拴着一个被湿实验验证过的分子。它的正确打开方式是\"AI时代的水电煤\"。两万余名研发人员是另一种形式的湿实验资产。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1790048109155811084","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["AGIX","BK1161","IBBQ","AIPO","LNGR","ARTY","VTHR","BK1191","159992","MEDX","01477","06978","CHAT","QTOC","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669210892","title":"多重利好持续发酵，创新药攻势再起！场内热门标的520880、159137逆市上扬","url":"https://stock-news.laohu8.com/highlight/detail?id=2669210892","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669210892?lang=zh_cn&edition=full","pubTime":"2026-09-23 14:31","pubTimestamp":1790145060,"startTime":"0","endTime":"0","summary":"100%创新药研发标的——港股通创新药ETF华宝逆市飘红。AI制药含量、CXO含量双高的港股通医疗ETF华宝逆市走强。政策端，创新药产业再获国家级战略背书。港股通创新药ETF华宝覆盖的50家创新药研发公司中，34家上半年实现盈利，归母净利同比正增长的有36家，占比超7成。全链布局创新药，可关注两个T+0交易工具：港股通创新药ETF华宝：标的指数100%布局创新药研发类公司，7成仓位押注创新药研发龙头。权重数据截至2026.8.31。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-23/doc-inisuxhc8551792.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","159137","06978","159992","520880","MEDX","LNGR","BK1574","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669170708","title":"【券商聚焦】广发证券首予四环医药（00460）买入评级 指医美与创新药进入兑现期","url":"https://stock-news.laohu8.com/highlight/detail?id=2669170708","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669170708?lang=zh_cn&edition=full","pubTime":"2026-09-23 14:04","pubTimestamp":1790143494,"startTime":"0","endTime":"0","summary":"金吾财讯 | 广发证券发布研报指，四环医药 早期起家于心脑血管等仿制药业务，在医药集采期主动求变，积极向医美与创新药业务转型，2025年利润扭亏为盈，26H1归母净利达2.2亿元，进入业绩兑现阶段。渠道端，至26H1医美渠道覆盖终端机构超9000家，于行业承压下实现医美收入6.9亿元，同增18.5%，税前利润3.4亿元，同增10.9%。公司加速剥离非核心资产，创新药减亏与医美利润兑现进一步改善报表质量。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992305","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978","01776","LNGR","KCE","MEDX","00460","159992","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188227323","title":"创新药概念走高，云顶新耀、药明巨诺-B涨逾5%，金斯瑞生物科技涨逾4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1188227323","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188227323?lang=zh_cn&edition=full","pubTime":"2026-09-23 11:01","pubTimestamp":1790132509,"startTime":"0","endTime":"0","summary":"9月23日，创新药概念走高，云顶新耀、药明巨诺-B涨逾5%，金斯瑞生物科技涨逾4%，康方生物、诺诚健华涨逾3%，基石药业涨逾2%，百济神州、药明生物、君实生物涨逾1%，信达生物跟涨。9月12-15日2026年世界肺癌大会召开，多项中国创新药临床数据集中亮相，康方生物依沃西单药OS数据、B7H3 ADC等成为焦点；与此同时，2026年国家医保目录谈判收官，商保创新药目录同步推进，支付端改革预期升温，\"出海商业化+支付改善\"的产业逻辑持续强化。","market":"hk","thumbnail":"https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672","02269","03347","02359","03759","06622","06978","06996","00241","09606","09688","09966","06606","09995","02137","06618","02268","01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669313171","title":"港股异动 | CRO概念股多数走高 创新药景气企业在手订单量价齐升 全球AI4S合作火热有望带来红利","url":"https://stock-news.laohu8.com/highlight/detail?id=2669313171","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669313171?lang=zh_cn&edition=full","pubTime":"2026-09-23 10:32","pubTimestamp":1790130773,"startTime":"0","endTime":"0","summary":"市场人士指，随着创新药BD交易持续活跃，药企研发资金趋于充裕，为抢占创新药研发窗口、保障项目进度，药企对外部研发服务的付费意愿提升，CRO企业在手订单呈“量价齐升”态势。此外，当前全球AI4S合作火热，国内CXO有望充分受益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1499676.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["06978","BK4588","KCAI","159992","MEDX","VXUS","LNGR","IBBQ","BK4585","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669171323","title":"港股异动 | CRO概念股多数走高 创新药景气企业在手订单量价齐升 全球AI4S合作火热有望带来红利","url":"https://stock-news.laohu8.com/highlight/detail?id=2669171323","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669171323?lang=zh_cn&edition=full","pubTime":"2026-09-23 10:32","pubTimestamp":1790130773,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","06978","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669145641","title":"4连板南华生物：细胞治疗相关技术与产品尚处于研发阶段无创新药上市或进入到临床试验阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2669145641","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669145641?lang=zh_cn&edition=full","pubTime":"2026-09-22 18:30","pubTimestamp":1790073047,"startTime":"0","endTime":"0","summary":"南华生物(000504.SZ)发布股票交易风险提示公告称，目前公司主营业务为生物医药和节能环保。其中，生物医药板块主要为客户提供干细胞、免疫细胞等生物资源的检测及储存服务，同时与多家临床研究机构合作，为其提供符合临床研究要求的细胞制备、检测等服务，公司细胞治疗相关技术与产品尚处于研发阶段，无创新药上市或进入到临床试验阶段；节能环保板块主要从事碳酸锂业务、废钢再生资源及配套加工销售等业务。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092200033929.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","000504","06978","BK0282","BK1161","159992","BK1574","BK0086","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669197470","title":"东方证券：创新药多路径突破 国产创新重塑新标准","url":"https://stock-news.laohu8.com/highlight/detail?id=2669197470","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669197470?lang=zh_cn&edition=full","pubTime":"2026-09-22 10:26","pubTimestamp":1790044006,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，东方证券发布研报称，本次WCLC大会进一步验证国产创新药在肺癌领域已由早期单臂数据逐步进入随机对照、全球开发和前线拓展阶段，肺癌治疗格局正由传统化疗、一代IO等主导，向ADC、二代IO和新一代靶向药多路径竞争演进。东方证券主要观点如下：SCLC：B7-H3 ADC时代来临TAISHAN-302和ARTEMIS-008两项III期研究均取得阳性结果，YL201和HS-20093相较拓扑替康显著改善PFS和OS，两项研究OSHR均为0.46，B7-H3 ADC有望成为复发SCLC的新标准疗法。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1499145.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06978","03958","BK0028","BK0276","BK1161","BK1564","LNGR","BK0188","IBBQ","BK1574","MEDX","159992","BK0012","BK0183","BK1147","600958"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669150459","title":"六大创新药企赛道与基本面对比","url":"https://stock-news.laohu8.com/highlight/detail?id=2669150459","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669150459?lang=zh_cn&edition=full","pubTime":"2026-09-21 19:01","pubTimestamp":1789988519,"startTime":"0","endTime":"0","summary":"为统一评测维度、保障对比分析的客观性，两大CXO龙头将单独纳入后续CXO赛道专项横评专栏，本文暂不展开对比分析。恒瑞医药——综合型全能龙头：作为国内创新药标杆企业，实现肿瘤、代谢、麻醉、罕见病等核心赛道全覆盖，管线厚度与技术壁垒处于行业第一梯队。2026年上半年创新药销售收入88.093亿元，占药品销售收入比重提升至63.2%。企业主动规避同质化严重的me-too红海赛道，聚焦慢病刚需与差异化肿瘤靶点。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1789873725771944898","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["159992","LNGR","BK1161","BK1574","MEDX","IBBQ","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669155020","title":"安科生物(300009.SZ)：创新药物注射用AK2405临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2669155020","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669155020?lang=zh_cn&edition=full","pubTime":"2026-09-21 16:01","pubTimestamp":1789977701,"startTime":"0","endTime":"0","summary":"智通财经APP讯，安科生物(300009.SZ)发布公告，近日，公司自主研发的创新药物注射用AK2405的临床试验申请获得国家药品监督管理局受理。注射用AK2405是一款靶向HER2的抗体偶联药物(ADC)，临床前研究已证实注射用AK2405具有高特异性和高抗肿瘤活性。该产品注册分类为治疗用生物制品1类：创新型生物制品，拟定适应症为晚期恶性实体瘤。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1498679.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","PSYK","BK0070","06978","300009","MDTX","159992","BK0042","LNGR","BMED","IBBJ","BK1161","BK0239","BK0060","IBBQ","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669253155","title":"恩华药业：创新药开发是企业的希望与未来","url":"https://stock-news.laohu8.com/highlight/detail?id=2669253155","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669253155?lang=zh_cn&edition=full","pubTime":"2026-09-21 15:54","pubTimestamp":1789977253,"startTime":"0","endTime":"0","summary":"证券之星消息，恩华药业(002262)09月21日在投资者关系平台上答复投资者关心的问题。投资者提问：公司业务目前面临新旧动能切换，并且出海还在初步，请问未来公司各大板块发展战略优先级是新药还是出海？恩华药业回复：根据战略规划，公司业务发展有着清晰的路径和可持续的动能支持。创新药开发是企业的希望与未来，目前促进创新药在国内落地是第一要务；同时，国际化也是公司战略目标之一，出海是公司长期愿景，是跟随产品管线不断完善的后手布局，公司一直在积极探索开拓国际市场。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100016467.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","LU1064130708.USD","159992","BK0070","LU2148510915.USD","002262","BK1574","LU1064131003.USD","BK0239","06978","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669553711","title":"天士力：公司拥有在研创新药33项","url":"https://stock-news.laohu8.com/highlight/detail?id=2669553711","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669553711?lang=zh_cn&edition=full","pubTime":"2026-09-21 15:36","pubTimestamp":1789976203,"startTime":"0","endTime":"0","summary":"证券之星消息，天士力(600535)09月21日在投资者关系平台上答复投资者关心的问题。投资者提问：公司Ⅲ期临床可有重磅产品？天士力回复：感谢您的关注，根据公司2026年半年报，公司拥有在研创新药33项（上半年神经/精神领域新立项2项），其中处于NDA/Pre NDA阶段3项，处于临床II、III期阶段18项。产品详细信息请参考2026年半年报P17页公司重点创新产品研发进度表，谢谢。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：沈彬","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100014190.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK1161","BK0028","600535","BK0239","BK1574","BK0012","BK0183","BK0196","159992","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669535961","title":"花旗：医药工业发展“十五五”规划利好创新药及医疗器械 首选石药集团(01093)等","url":"https://stock-news.laohu8.com/highlight/detail?id=2669535961","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669535961?lang=zh_cn&edition=full","pubTime":"2026-09-21 15:03","pubTimestamp":1789974221,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，花旗发布研报称，工信部等部门联合发布《医药工业发展“十五五”规划》，核心是推动中国医药工业由规模驱动增长转向创新驱动、质量导向发展，并明确提出到2030年跻身世界领先行列的目标。规划涵盖创新药、创新医疗器械、人工智能驱动药物发现，以及CDMO/CRO等技术领域，显示政策正对整条价值链作出广泛支持。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1498647.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0516422366.SGD","LU1242518857.USD","02269","06990","LU0029874061.USD","BK4588","LNGR","LU3063872942.SGD","MEDX","RSPH","LU1807302812.USD","KURE","IEIH","GDOC","LGHT","LU1226287875.USD","159992","HK0000165453.HKD","LU0455707207.USD","01276","LU1244550494.USD","FTXO","LU0067412154.USD","BK4566","IYF","LU2417539215.USD","03347","TFNS","PTH","SG9999002463.SGD","06978","LU0516422440.USD","LU0359201885.HKD","LU1152091168.USD","LU0456827905.SGD","HART","BK1576","01801","AGNG","LU1366192091.USD","IE00B543WZ88.USD","IBBQ","LU0029874905.USD","LU0128525689.USD","159883","09996","LU0561508036.HKD","MDEV","LU1242518931.SGD","01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669096130","title":"【券商聚焦】浙商证券维持先声药业（02096）买入评级 指创新药与BD共同兑现","url":"https://stock-news.laohu8.com/highlight/detail?id=2669096130","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669096130?lang=zh_cn&edition=full","pubTime":"2026-09-21 14:15","pubTimestamp":1789971349,"startTime":"0","endTime":"0","summary":"金吾财讯 | 浙商证券发布研报指，先声药业 2026H1业绩收入利润双高增，创新药与BD共同兑现，TCE资产再次授权。2026年上半年营业收入45.80亿元人民币，同比增长27.8%；归母净利润8.29亿元人民币，同比增长37.9%。经营活动现金净流入16.05亿元人民币，同比增长约86.0%。对外授权方面，截至2026H1，公司已就五项自主研发创新药物与国际药企达成合作，交易总金额超过46亿美元；2026H1确认许可收入4.05亿元人民币，上年同期1.22亿元人民币。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/MWQ0NzJkZTcxMzM4ODY4MjA2MzM0OTUz.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWQ0NzJkZTcxMzM4ODY4MjA2MzM0OTUz.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992106","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096","159992","LNGR","MEDX","IBBQ","601878","KCE","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669130187","title":"大行评级丨花旗：医药工业发展“十五五”规划利好创新药及医疗器械，首选恒瑞医药及信达生物等","url":"https://stock-news.laohu8.com/highlight/detail?id=2669130187","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669130187?lang=zh_cn&edition=full","pubTime":"2026-09-21 14:14","pubTimestamp":1789971280,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU1969619763.USD","BK1161","LU2097828474.EUR","LU0607220059.USD","BK1589","LU2097828631.EUR","HK0000165453.HKD","LU1188198961.HKD","LU2543165471.USD","LU0463099449.HKD","BK1574","LU0326950275.SGD","LU0455707207.USD","BK1583","BK1100","BK1191","LU2097828557.USD","LU2242644610.SGD","LU2097828714.EUR","LU0502904849.HKD","LU0149534421.HKD","LU0244354667.USD","LU1023057109.AUD","KURE","LU2097828805.USD","01276","06978","LU1831875114.USD","LU2328871848.SGD","LU0359201885.HKD","LU0359202008.SGD","01801","09996","LU2488822045.USD","LU0359201612.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eaal.net","stockEarnings":[{"period":"1week","weight":-0.0361},{"period":"1month","weight":0.0667},{"period":"3month","weight":-0.2453},{"period":"6month","weight":-0.8561},{"period":"1year","weight":-0.913},{"period":"ytd","weight":-0.8635}],"compareEarnings":[{"period":"1week","weight":0.0064},{"period":"1month","weight":-0.0294},{"period":"3month","weight":0.0922},{"period":"6month","weight":-0.0076},{"period":"1year","weight":-0.0663},{"period":"ytd","weight":-0.0339}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"永泰生物制药有限公司是一家主要从事用于治疗癌症的细胞免疫产品的研发、制造及商业化的投资控股公司。该公司的非转基因细胞产品管线包括扩增活化淋巴细胞（EAL）和6B11-OCIK注射液。该公司的嵌合抗原受体T（CAR-T）细胞产品管线包括CAR-T-19注射液、迪诺仑赛注射液和aT19注射液。该公司的T细胞受体工程化T细胞疗法（TCR-T）细胞产品管线包括YT003、YT008及YT007。该公司主要在中国市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.074078},{"month":2,"riseRate":0.666667,"avgChangeRate":0.181642},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.080929},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.167652},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.073624},{"month":6,"riseRate":0.666667,"avgChangeRate":0.015994},{"month":7,"riseRate":0.166667,"avgChangeRate":-0.057223},{"month":8,"riseRate":0.571429,"avgChangeRate":0.024873},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.027029},{"month":10,"riseRate":0.5,"avgChangeRate":-0.057833},{"month":11,"riseRate":0.5,"avgChangeRate":0.001253},{"month":12,"riseRate":0.666667,"avgChangeRate":0.067669}],"exchange":"SEHK","name":"永泰生物-B","nameEN":"IMMUNOTECH-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"永泰生物-B,06978,永泰生物-B股票,永泰生物-B股票老虎,永泰生物-B股票老虎国际,永泰生物-B行情,永泰生物-B股票行情,永泰生物-B股价,永泰生物-B股市,永泰生物-B股票价格,永泰生物-B股票交易,永泰生物-B股票购买,永泰生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}